T1	Participants 314 336	assigned 5362 patients
T2	Participants 774 794	185 of 2654 patients
T3	Participants 829 849	210 of 2641 patients
T4	Participants 1044 1059	cangrelor group
T5	Participants 1082 1095	placebo group
T6	Participants 1461 1476	cangrelor group
T7	Participants 1493 1506	placebo group
T8	Participants 1573 1588	cangrelor group
T9	Participants 1860 1875	cangrelor group
